Vietnam's pharmaceutical raw material market steadies after sharp price correction

Vietnam's pharmaceutical raw material market steadies after sharp correction

Vietnam's market for pharmaceuticals and pharmaceutical raw materials showed early signs of stabilization in the first half of 2026, according to a market review published by vinanet.vn. The trade information portal reported that the period was defined by a deep price correction and a broad restructuring of the global pharmaceutical supply chain, followed by a mild easing in conditions.

A sharp start-of-year decline

According to vinanet.vn, prices for pharmaceuticals and for raw and auxiliary materials — known locally as NPL — fell steeply at the start of 2026. The portal tied the drop to a strong reshaping of global supply chains, as sourcing patterns for active pharmaceutical ingredients and other inputs shifted. For Vietnam, which depends heavily on imported inputs to supply its domestic drug manufacturing, movements in global raw material prices feed directly into local costs.

The review described the first six months of the year as a phase of deep adjustment rather than steady trading, with the supply chain still absorbing the effects of the earlier fall. Buyers that had locked in higher prices before the decline faced the sharpest pressure on margins.

Signs of stabilization

After the initial slide, vinanet.vn reported that the market began to show signs of gradual stabilization through the review period. The report frames this as a tentative easing rather than a full recovery, with conditions settling once the first shock to global supply chains had passed.

For importers and manufacturers, a steadier raw material market reduces the uncertainty that complicates procurement and inventory planning. Stable input prices make it easier to set finished-product prices and to negotiate supply contracts, whereas sharp swings force buyers to hedge or to hold larger stocks as protection.

Because Vietnam sources much of its active ingredient supply abroad, the local market tends to track global price cycles with a short lag. A calmer global market therefore tends to show up quickly in domestic input costs.

Outlook for the second half

The vinanet.vn review also carried a forecast for the pharmaceutical and raw material market, pointing to the second half of 2026 as the test of whether the early stabilization holds. The portal linked the outlook to the pace at which global pharmaceutical supply chains complete their restructuring.

For exporters supplying Vietnam and for domestic drug makers, the direction of raw material prices will shape margins in the months ahead. A durable stabilization would support more predictable trade flows in active pharmaceutical ingredients, excipients and finished medicines, while renewed volatility in global sourcing could quickly reverse the recent calm.

Much will depend on how quickly suppliers of active ingredients settle into new trade routes and how demand from downstream drug manufacturing evolves. Until that picture is clear, procurement teams are likely to favour shorter contracts and closer monitoring of global price signals.